Not-for-profit catalyst
SU2C's Catalyst program connects companies and compounds with academics
Two not-for-profit partners are marrying academic researchers with pharmas to help the companies exploit the talent in the scientific community to answer key questions about the companies' cancer compounds. Stand Up To Cancer (SU2C) and its partner American Association for Cancer Research (AACR) have created a Catalyst program that will issue awards to researchers interested in collaborating with other academic groups to accelerate research into cancer treatments or prevention.
SU2C recruited founding collaborator Merck & Co. Inc. (NYSE:MRK), as well as Bristol-Myers Squibb Co. (NYSE:BMY) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), to provide funding and compounds for the program. The idea is that companies will work through SU2C to find investigators interested in conducting research into repurposing approved drugs or on other compounds in their cancer pipelines...